IRLAB: Q3 2023 Update - Redeye

Redeye updates its view of IRLAB following the Q3 report and largely reiterate our previous view. We think that the next significant trigger is the outcome of the end-of-phase II meeting on Mesdopetam, which will determine the risk-reward profile for future development of the drug candidate in our view.

Länk till analysen i sin helhet: https://www.redeye.se/research/950988/irlab-q3-2023-update?utm_source=finwire&utm_medium=RSS